GLSI Greenwich LifeSciences, Inc. Stock Quote

GLSI [NASD]

Index	-	P/E	-	EPS (ttm)	-0.14	Insider Own	17.20%	Shs Outstand	14.90M	Perf Week	-9.39%
Market Cap	468.14M	Forward P/E	-	EPS next Y	-1.29	Insider Trans	0.50%	Shs Float	2.54M	Perf Month	-28.20%
Income	-1.90M	PEG	-	EPS next Q	-0.26	Inst Own	0.90%	Short Float	12.48%	Perf Quarter	-9.41%
Sales	-	P/S	-	EPS this Y	48.80%	Inst Trans	-0.84%	Short Ratio	0.48	Perf Half Y	922.79%
Book/sh	1.85	P/B	19.41	EPS next Y	-11.20%	ROA	-21.10%	Target Price	-	Perf Year	-
Cash/sh	2.20	P/C	16.31	EPS next 5Y	-	ROE	-25.30%	52W Range	3.26 - 158.07	Perf YTD	-1.56%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-77.29%	Beta	-
Dividend %	-	Quick Ratio	27.40	Sales past 5Y	-	Gross Margin	-	52W Low	1000.55%	ATR	4.60
Employees	1	Current Ratio	27.40	Sales Q/Q	-	Oper. Margin	-	RSI (14)	48.66	Volatility	6.91% 13.19%
Optionable	No	Debt/Eq	0.01	EPS Q/Q	-174.70%	Profit Margin	-	Rel Volume	0.19	Prev Close	34.09
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	665.61K	Price	35.90
Recom	2.00	SMA20	-6.57%	SMA50	4.44%	SMA200	39.07%	Volume	127,852	Change	5.31%

Apr-21-21 09:42AM	1 Drug, 1 Mission: What Should Investors Expect for Greenwich Life Sciences? Motley Fool +10.87%
Apr-19-21 10:30AM	Greenwich LifeSciences Hires Industry Expert Dr. Christine Fischette to Lead Business Development & Advise on Commercialization Business Wire
Apr-16-21 02:26AM	Trade Alert: The CEO, CFO & Director Of Greenwich LifeSciences, Inc. (NASDAQ:GLSI), Snehal Patel, Has Just Spent US$100k Buying A Few More Shares Simply Wall St.
Apr-14-21 06:00AM	Greenwich LifeSciences Announces Update of GP2 Phase III Clinical Trial Design at the 2021 AACR Annual Meeting Business Wire
Apr-12-21 04:17PM	Why Greenwich LifeSciences Stock Tanked Today Motley Fool -26.96%
05:52AM	REPEAT/Greenwich LifeSciences Presents Phase IIb Poster, Published April 10th at 2021 AACR Annual Meeting, Showing GP2 Immune Response Peaked at 6 Months, Resulting in 100% Disease Free Survival from Recurring Breast Cancer Business Wire
Apr-10-21 04:13PM	Greenwich LifeSciences Presents Immune Response Phase IIb Poster, Published Today at AACR 2021, Showing Peak Immunity after 6 Months of GP2 Treatment, Resulting in 100% Disease Free Survival from Recurring Breast Cancer Business Wire
05:13AM	15 Best Stocks in the Past Week: Square, Roku, Pinterest TheStreet.com
Apr-09-21 12:00PM	Why Greenwich LifeSciences Stock Is Rising Today Motley Fool +6.14%
06:56AM	Greenwich LifeSciences' Stock Is Trading Higher After Breast Cancer Immunotherapy Shows 0% Recurrences Over 5 Years Follow-up Benzinga
05:00AM	Greenwich LifeSciences Reports Robust Immune Response Phase IIb Data Supporting GP2 Clinical Outcome of 0% Metastatic Breast Cancer Recurrences Over 5 Years of Follow-up Business Wire
Apr-02-21 08:39AM	Greenwich LifeSciences Is Both a Sound Investment and a Feel-Good Buy InvestorPlace
Mar-25-21 03:37AM	Read This Before Selling Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Shares Simply Wall St. -5.39%
Mar-24-21 03:39PM	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Greenwich LifeSciences, Inc.- GLSI Newsfile
Mar-23-21 06:00AM	Greenwich LifeSciences CEO to Participate on Cancer Panel and to Present at Benzinga Biotech Conference Business Wire
Mar-22-21 12:31PM	Greenwich LifeSciences Could See Another Spike in Stock in Early April Benzinga
Mar-11-21 06:00AM	Greenwich LifeSciences Updates 2021 Timeline & Announces Two Upcoming Presentations at the American Association for Cancer Research Annual Meeting Business Wire -8.30%
Mar-10-21 07:59PM	Greenwich LifeSciences CEO to be Interviewed Live on Benzingas Power Hour Business Wire -8.93%
Mar-08-21 03:57PM	Why Greenwich LifeSciences Stock Skyrocketed Today Motley Fool +61.74%
06:00AM	Greenwich LifeSciences Hires Industry Expert, Dr. Jaye Thompson, to Manage Phase III Clinical Trial for Recurring Breast Cancer Business Wire
Mar-02-21 06:00AM	Greenwich LifeSciences to Present at Multiple Investor Conferences, Including H.C. Wainwright Global Life Sciences and BIO-Europe Spring Conferences Business Wire -8.52%
Feb-25-21 06:00AM	Greenwich LifeSciences Announces Acceptance of Two Abstracts at Upcoming Major Cancer Conference Business Wire
Feb-02-21 09:41AM	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Greenwich LifeSciences, Inc.- GLSI Newsfile
Jan-29-21 11:33AM	Greenwich LifeSciences Announces Exercise and Closing of Underwriters Over-Allotment Option Business Wire +9.65%
06:00AM	Greenwich LifeSciences CEO Interview to Air on Bloomberg International on the RedChip Money Report Business Wire
Jan-21-21 06:00AM	Greenwich LifeSciences to Present at B. Riley Securities and BIO CEO & Investor Conferences Business Wire
Jan-08-21 06:00AM	Greenwich LifeSciences to Participate in Multiple Virtual Investor Conferences During 2021 JP Morgan Healthcare Week Business Wire
Jan-05-21 12:52PM	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Greenwich LifeSciences, Inc.- GLSI Newsfile
06:00AM	Greenwich LifeSciences LD Micro Presentation Replay Now Available Business Wire
Dec-28-20 10:35AM	This Was the Top-Performing IPO in 2020 Motley Fool
Dec-25-20 02:02AM	Do Institutions Own Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Shares? Simply Wall St.
Dec-24-20 06:00AM	Greenwich LifeSciences to Ring Nasdaq Opening Bell on December 28 Business Wire
Dec-22-20 10:12AM	Greenwich LifeSciences, Inc. Announces Closing of Public Offering of Common Stock Business Wire
Dec-18-20 02:47PM	Why Greenwich LifeSciences Stock Is Plunging Today Motley Fool -14.15%
06:00AM	Greenwich LifeSciences, Inc. Prices $26.4 Million Upsized Public Offering of Common Stock Business Wire
Dec-16-20 02:53PM	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Greenwich LifeSciences, Inc.- GLSI Newsfile -7.96%
Dec-15-20 06:00AM	Greenwich LifeSciences Announces Option Agreement for Pre-clinical Coronavirus Vaccine Candidates Business Wire +13.03%
Dec-11-20 08:00AM	How 'Regular Investors' Made Quick 130%-Plus Gains On IPOs Investor's Business Daily -22.46%
06:00AM	Greenwich LifeSciences Announces Poster Presentation on Its GP2 Phase III Clinical Trial Design for Recurring Breast Cancer Business Wire
Dec-10-20 04:16PM	Wild Ride Continues For This Biotech Stock With A 998% Single-Day Gain Investor's Business Daily +26.48%
11:51AM	UPDATE: Immutep shares soar 190% on positive results in trial of breast cancer treatment MarketWatch
Dec-09-20 02:29PM	Greenwich LifeScience stock skyrockets more than 2,000% after upbeat data on breast cancer treatment MarketWatch +998.35%
09:05AM	Greenwich LifeSciences Announces Poster Presentation of Five Year Data for GP2 Phase IIb Clinical Trial, Showing 0% Recurrence of Breast Cancer Business Wire
Dec-03-20 07:00AM	Greenwich LifeSciences Announces New Manufacturing Agreement for its Planned Phase III Clinical Trial and Enters into Lease for Office and Lab Space Business Wire
Dec-02-20 07:00AM	Greenwich LifeSciences to Present at the Annual LD Micro Main Event Business Wire
Nov-23-20 07:00AM	Greenwich LifeSciences Announces Second Publication and Second Poster Presentation of Phase III Clinical Trial of Potential Breakthrough Technology for Recurring Breast Cancer Business Wire
Nov-18-20 07:00AM	Greenwich LifeSciences Announces Publication of Positive Phase IIb Clinical Trial Data for GP2, Its Lead Drug Candidate for the Prevention of Recurring Breast Cancer Business Wire +19.71%
Nov-12-20 09:00AM	Greenwich LifeSciences, Inc. Announces Partnership with Baylor College of Medicine for its Planned Phase III Clinical Trial Business Wire
Nov-05-20 09:00AM	Greenwich LifeSciences, Inc. to Participate at Texas Life Sciences Forum Investor Conference Business Wire
Oct-08-20 08:00AM	Greenwich LifeSciences, Inc. Announces Acceptance of Two Abstracts at Upcoming Major Breast Cancer Conference Business Wire +8.89%
Oct-07-20 08:00AM	Greenwich LifeSciences, Inc. to Participate at Upcoming Investor and Partnering Conferences Business Wire
Oct-06-20 04:01PM	Greenwich LifeSciences, Inc. Announces Completion of Manufacturing of Drug for its Planned Phase III Clinical Trial Business Wire +5.14%
Sep-29-20 04:17PM	Greenwich LifeSciences, Inc. Announces Closing of Initial Public Offering Business Wire -6.31%

Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent recurrence of breast cancer following surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Patel Snehal	CEO and CFO	Apr 13	Buy	36.98	2,700	99,853	1,189,539	Apr 14 07:30 AM
Hallock Kenneth	Director	Nov 24	Buy	5.39	1,000	5,386	397,004	Nov 27 07:00 AM
Daugherty Frank Joseph	Chief Medical Officer	Nov 23	Buy	5.10	1,000	5,100	87,010	Nov 25 07:00 AM
Hallock Kenneth	Director	Nov 20	Buy	5.37	1,000	5,370	396,004	Nov 24 08:00 AM
McWilliams David	Director	Nov 20	Buy	5.40	1,500	8,100	620,101	Nov 24 08:00 AM
Rothe Eric	Director	Nov 20	Buy	5.40	2,000	10,800	313,226	Nov 24 08:00 AM
Patel Snehal	CEO and CFO	Nov 19	Buy	5.40	2,000	10,795	1,186,839	Nov 20 07:00 AM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience